Cerebral aneurysm future or investigational therapies: Difference between revisions
| Line 1: | Line 1: | ||
== Investigational Therapies == | ==Investigational Therapies== | ||
__NOTOC__ | __NOTOC__ | ||
{{Cerebral aneurysm}} | {{Cerebral aneurysm}} | ||
| Line 7: | Line 7: | ||
Currently, there are two main classes of pharmacology, used for this purpose. | Currently, there are two main classes of pharmacology, used for this purpose. | ||
=== Cell Therapies: === | ===Cell Therapies:=== | ||
* Endothelial Progenitor cells (EPCs) | *Endothelial Progenitor cells (EPCs) | ||
* Mesenchymal stem cells (MSCs) | *Mesenchymal stem cells (MSCs) | ||
* Vascular smooth muscle cells (VSMs) | *Vascular smooth muscle cells (VSMs) | ||
* Fibroblasts | *Fibroblasts | ||
=== Drug Therapies: === | ===Drug Therapies:=== | ||
* MCP-1 Inhibitors | *MCP-1 Inhibitors | ||
* ACE inhibitors | *ACE inhibitors | ||
* TNF-alpha Inhibitors | *TNF-alpha Inhibitors | ||
== Future Perspectives: == | ==Future Perspectives:== | ||
The Subarachnoid Hemorrhage is consider as a major cause of Cerebral Aneurysm. The main goal for management of cerebral aneurysm is prevention of rupture or re-rupture. | The Subarachnoid Hemorrhage is consider as a major cause of Cerebral Aneurysm. The main goal for management of cerebral aneurysm is prevention of rupture or re-rupture. | ||
| Line 30: | Line 30: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
# Aoki T, Nozaki K. Preemptive Medicine for Cerebral Aneurysms. Neurol Med Chir (Tokyo). 2016 Sep 15;56(9):552-68. doi: 10.2176/nmc.st.2016-0063. Epub 2016 Apr 6. PMID: 27053328; PMCID: PMC5027238. | |||
[[Category:Neurology]] | [[Category:Neurology]] | ||
Revision as of 14:26, 23 March 2022
Investigational Therapies
|
Cerebral aneurysm Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cerebral aneurysm future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cerebral aneurysm future or investigational therapies |
|
FDA on Cerebral aneurysm future or investigational therapies |
|
CDC on Cerebral aneurysm future or investigational therapies |
|
Cerebral aneurysm future or investigational therapies in the news |
|
Blogs on Cerebral aneurysm future or investigational therapies |
|
Risk calculators and risk factors for Cerebral aneurysm future or investigational therapies |
In order to get cure from Cerebral Aneurysm, the most focusing should be reconstruction of vascular wall with normal endothelialization.
Currently, there are two main classes of pharmacology, used for this purpose.
Cell Therapies:
- Endothelial Progenitor cells (EPCs)
- Mesenchymal stem cells (MSCs)
- Vascular smooth muscle cells (VSMs)
- Fibroblasts
Drug Therapies:
- MCP-1 Inhibitors
- ACE inhibitors
- TNF-alpha Inhibitors
Future Perspectives:
The Subarachnoid Hemorrhage is consider as a major cause of Cerebral Aneurysm. The main goal for management of cerebral aneurysm is prevention of rupture or re-rupture.
The main management for CA is currently surgical procedures which only modify morphological aspects of aneurysm and cannot completely prevent from re-rupture.
Therefore, it is necessary to develop more effective and less risky treatments that are also fall in the line of cost-effectiveness.
References
- Aoki T, Nozaki K. Preemptive Medicine for Cerebral Aneurysms. Neurol Med Chir (Tokyo). 2016 Sep 15;56(9):552-68. doi: 10.2176/nmc.st.2016-0063. Epub 2016 Apr 6. PMID: 27053328; PMCID: PMC5027238.